Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
StockNews.AI ยท 2 hours
AI Summary
Mirum and Incyte are set to disclose pivotal Phase 2 PROGRESS results for zilurgisertib at ENDO 2026, highlighting Cohort 1 data that underpins the NDA submitted to the FDA. The NDA has been accepted with Priority Review and a PDUFA date of Sept 26, 2026, marking a near-term regulatory hinge for zilurgisertib in FOP and potential global commercialization via Mirum.
Sentiment Rationale
Near-term regulatory milestones (PDUFA date) and the ENDO data readout could reprice INCY shares positively if data are favorable; otherwise, uncertainty remains until data are disclosed.
Trading Thesis
INCY could re-rate on positive ENDO data and the Sept. 26 PDUFA, driving near-term upside.
Market-Moving
- END0 2026 ENDO presentation and NDA timeline are near-term catalysts.
- Positive PROGRESS Cohort 1 data could lift INCY valuation expectations.
- Exclusive Mirum license with worldwide rights enhances collaboration value for INCY.
Key Facts
- Incyte and Mirum to present zilurgisertib PROGRESS Phase 2 data at ENDO 2026.
- NDA accepted by FDA with Priority Review; PDUFA date set for Sept 26, 2026.
- Mirum licensed zilurgisertib from Incyte in April 2026 for worldwide rights.
- ENDO 2026 abstract ORF37-04 scheduled for Sunday, June 14, 2026.
Companies Mentioned
- Incyte (INCY): Collaborator on zilurgisertib; potential regulatory and commercial upside tied to PROGRESS data and NDA outcomes.
- Mirum Pharmaceuticals (MIRM): Exclusive worldwide licensee for zilurgisertib; joint development with Incyte supports near-term FOP program leverage.
Corporate Developments
Category: Corporate Developments. The article centers on strategic licensing, collaboration, and regulatory progress for zilurgisertib, creating near-term catalysts for INCY via the NDA/PDUFA timeline and the ongoing Mirum partnership.